HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
INSIDE INDUSTRY
Oak Therapeutics completes Phase 1 of NIH grant to develop formulation for tuberculosis
Oak has created a novel formulation using encapsulation technologies, suitable matrix components, flavoring ingredients and other ODS formulation parameters to produce a product prototype containing 300mg of Isoniazid, that is rapidly dissolving and mucoadhesive, as an anti-tuberculosis treatment option.

CURE Pharmaceutical, a disruptive drug delivery technology company, announced that its subsidiary company, Oak Therapeutics, has completed a critical milestone of its Phase I Small Business Innovative Research Contract (SBIR) from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/ NIAID) to develop a formulation for 300mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip (ODS) as an anti-tuberculosis treatment option.

Under the Phase I contract issued to Oak by the NIAID in May 2016, Oak sought to establish the technical merit, feasibility and commercial potential for the reformulation of isoniazid, an oral antibacterial prescription medicine for the prevention and treatment of Tuberculosis, as an ODS.

Oak has created a novel formulation using encapsulation technologies, suitable matrix components, flavoring ingredients and other ODS formulation parameters to produce a product prototype containing 300mg of Isoniazid, that is both rapidly dissolving and mucoadhesive. This represents an industry-first, and a significant advance to CURE’s proprietary CureFilmTM drug delivery platform.

Patient adherence is a substantial health issue that is significantly magnified when dealing with long term treatments for diseases such as tuberculosis, the second most common infectious cause of death worldwide after HIV. A significant factor in suboptimal adherence may be the formulation of the drug. Furthermore, with Isoniazid included in the Best Practices for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics for 2015, isoniazid is an ideal candidate for reformulation as an ODS.

“The challenge was to find a way to create a strip that could deliver 300mg of drug while still dissolving in the mouth in less than a minute. We were able to invent exactly such a disruptive technology”, said Ed Maliski, President of Oak Therapeutics.

“Having this technology creates many new opportunities for future products for other antibiotics and for pain relievers,” said Rob Davidson, CEO of CURE. “Such drugs were previously not considered because of the high dose needed.”

Oak is currently in the application process for Phase II of the SBIR program, to continue its research and development and focus on manufacturing scale up, clinical trials and commercialization.

Source: CURE Pharmaceutical

Click here for the complete issue.

NEWS CRUNCH  
news Genetically boosting the nutritional value of corn could benefit millions
news Inhibitor Pariet obtained approval of additional dosage in Japan for maintenance therapy of proton pump inhibitor resistant reflux esophagitis
news Dornier MedTech opens Asia Pacific Headquarters & Global Clinical Innovation Centre in Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy